In Contrast, Uptake of Biosimilar Insulins will be Significantly Slower Across the Major Pharmaceutical Markets, According to Survey Results from Endocrinologists
EXTON, Pa.--(BUSINESS WIRE)-- BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that over 60 percent of surveyed nephrologists in the United States expect to begin prescribing biosimilar epoetin alfa within the first 12 months of launch. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoiesis-stimulating Agents, Insulin, and Human Growth Hormone, US nephrologists’ predicted speed of uptake is on a par with uptake rates reported among surveyed German nephrologists who have one of the highest usage rates of biosimilar epoetin alfa across Europe.
“We also found that US nephrologists expect to prescribe biosimilar darbepoetin alfa to a greater percentage of their eligible patients than their French and German peers,” said Biosimilars Advisory Services’ Director, Andrew Merron, Ph.D. “This suggests that biosimilar erythropoiesis-stimulating agents (ESAs) will experience deeper, as well as more rapid, market penetration in the United States than we’ve seen in Europe as a whole.”
Survey results also indicate that endocrinologists’ adoption of biosimilar insulins will be substantially weaker than nephrologists’ uptake of ESAs; we expect the market share of biosimilar insulins to reach 8 percent by 2021, compared with 36 percent for the ESAs across the United States, Europe and Japan. A leading factor in the lower uptake of insulins is the expected narrow price differential between biosimilar insulins and their reference products, in comparison to the ESA class.
Surveyed nephrologists and endocrinologists were also questioned on many other topics which are pivotal to understanding the current and future uptake of biosimilars, including their level of familiarity with biosimilars, concerns about biosimilars, drivers and constrainers of adoption, views on indication extrapolation, attitudes towards reimbursement, the expected impact of ‘biobetters’ and the clinical trial requirements for biosimilars.
These findings are from the Biosimilars Advisory Service which provides insight and analysis which is vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst insight addressing key market changes and opportunities, therapeutic area-specific primary research and interactive annualized 10-year forecasts.
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
Source: BioTrends Research Group